Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Semi-annual Business Results
December 6, 2004
- Semi-annual Business Results
December 6, 2004
- Top 28 Post 0.1% Decline in Non-consolidated Sales
December 6, 2004
- VITAL-NET: Profits Down Sharply Despite Growth in Sales
December 6, 2004
- Japan Should Boost Healthcare Spending to 9% of GDP: Mr Butler of PhRMA
December 6, 2004
- SSP: Sales of Rx Drugs Up 6.1% to \5.8 Bil.
December 6, 2004
- NEW PRODUCTS
December 6, 2004
- SSP to Concentrate on Consumer Healthcare: VP Yamashita
December 6, 2004
- Wyeth's Enbrel Receives Import Approval
December 6, 2004
- Zeria: Sales Up 4.2% to \28,486 Mil.
December 6, 2004
- Expanding Indications for Cancer Combination Therapy Approved
December 6, 2004
- Fuso: Drug Sales, Up 0.5% to \20.6 Bil.
December 6, 2004
- PMDA to Increase Its Number of GMP Inspectors, Biostatisticians
December 6, 2004
- Nikken Chemicals: Profits Up Sharply Despite Decline in Sales
December 6, 2004
- US, EU, Nippon Keidanren Present Requests on Regulatory Reform
December 6, 2004
- Teikoku Hormone: Pharma, Animal Health Segments Post Lower Sales
December 6, 2004
- REGULATORY NEWS IN BRIEF
December 6, 2004
- Wakamoto: Ethical Drug Div. Posts Declines in Sales, Profits
December 6, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 6, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 6, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…